Status:
COMPLETED
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Lead Sponsor:
Pfizer
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Eligibility Criteria
Inclusion
- Diagnosis of metastatic, progressive hormone refractory prostate cancer
- Adequate bone marrow, liver and kidney function
Exclusion
- Previous treatment with chemotherapy
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00313781
Start Date
May 1 2006
End Date
December 1 2011
Last Update
April 11 2013
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States, 90048
2
Pfizer Investigational Site
New York, New York, United States, 10032
3
Pfizer Investigational Site
Cleveland, Ohio, United States, 44106
4
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195-0001